Atorvastatin/CoenzymeQ10 in Congestive Heart Failure

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01925937

Enrollment

Registered

2013-08-20

Start date

2013-06-30

Completion date

Unknown

Last updated

2013-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Keywords

Coenzyme Q10, Atorvastatin, clinical trial, congestive heart failure

Brief summary

The aim of this study is to compare the effect of addition of combination of Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus addition of Atorvastatin alone on CHF outcomes.

Interventions

DRUGAtorvastatin

DRUGCoenzyme Q10

DRUGplacebo for coenzyme Q10

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Documented Congestive hear failure * Ejection Fraction less than 40 percent * Compensated heart failure without hospital admission during previous three months * No change in type and dose of medications in the last months * New York Heart Association Function Class 2 to 4

Exclusion criteria

* Acute coronary syndrome developing in the last month * Active myocarditis * Active pericarditis * Uncontrolled hypertension * Hepatic failure(Child B,C) * Pulmonary failure * Renal failure * Heart failure with KILLIP classification 3 and 4

Design outcomes

Primary

Measure	Time frame	Description
Change in cardiac Ejection Fraction (EF)	Baseline for the first time and after 4 months for the second time	For the determination of change in EF,cardiac EF was determined two times . Baseline :at the beginning of study(before intervention) and the second time after 4 months(after intervention).

Secondary

Measure	Time frame	Description
Change in New York Heart Association Function Class	Baseline for the first time and after 4 months for the second time	For the determination of change in New York Heart Association Function Class.it was determined two times .Baseline:at the beginning of study(before intervention)and the second time after 4 months(after intervention).

Countries

Iran

Contacts

Primary ContactAmin Nemati, MD

nemati@med.mui.ac.ir00989131009918

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026